Archived AES Symposia 2005
Impaired Consciousness In Epilepsy - Mechanisms and Consequences
Program Length: 2 hrs 14 min
Impaired consciousness during seizures has a major negative impact on patients quality of life, leading to injuries, cognitive lapses, and social stigma. While clinically important, unconsciousness in epilepsy has been a relatively neglected field in the past 25 years. Emerging technology now enables us to investigate fundamental mechanisms underlying normal consciousness and the impaired consciousness associated with epileptic seizures. Speakers in this symposium will discuss basic thalamocortical mechanisms in normal and impaired consciousness; neuropsychological testing and models of impaired attention during seizures; neuroimaging insights into epileptic unconsciousness; and EEG changes associated with loss of consciousness in different types of seizures. Speakers will also discuss the clinical consequences of impaired consciousness in epilepsy, and therapeutic goals will be identified.
At the conclusion of this activity, participants should be able to:
- Discuss basic thalamocortical circuits underlying normal consciousness and loss of consciousness in epilepsy
- Interpret neuropsychological data showing impaired attention during seizures
- Review functional neuroimaging results associated with loss of consciousness during seizures
- Identify EEG changes leading to epileptic unconsciousness
- Examine patient risks and other adverse consequences associated with impaired consciousness during seizures, and therapeutic goals to reduce these risks.
Epileptologists, neurologists, pharmacists, nurses, and other healthcare professionals involved with the care of people with epilepsy.
Chair: Hal Blumenfeld, M.D., Ph.D.
This program and its repurposing on the AES Web site with CME credit is supported by an educational grant from GlaxoSmithKline.
Disclosure: It is the policy of the American Epilepsy Society that all faculty participating in continuing medical education activities are expected to disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. The American Epilepsy Society adheres to the ACCMEs Essential Areas and Policies regarding industry support of continuing medical education. Disclosure by faculty of commercial relationships, if any, and discussions of unlabeled or unapproved uses will be made.
Hal Blumenfeld, MD, PhD reports he has nothing to disclose.
David A. McCormick, PhD reports he has nothing to disclose.
Kimford J. Meador, MD, Grants: GlaxoSmithKline, SAM Technology, UCB Pharma Consultant: Abbott, Cyberonics, GlaxoSmithKline, Neuropace, Ortho-McNeil, UCB Pharma. Honorarium: GlaxoSmithKline, Ortho-McNeil, UCB Pharma
Allan F. Mirsky, PhD reports he has nothing to disclose.
Nicholas D. Schiff, MD reports he has nothing to disclose.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.